To prevent oestrogen receptor alpha positive (ERα+) breast cancer, nemorosone may successfully be used as an adjuvant owing to its inhibitory action toward 17-β-estradiol (E2) without any genotoxicity. This evidence concerns the gene ESR1 and breast carcinoma.